| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF6165-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB6165-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-24564-25ul | |||
| Azide and BSA Free | NBP3-43833 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-16945-20ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26571-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-24565-25ul | |||
| Azide and BSA Free | NBP3-43834 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26424-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-21531-50ul | |||
![Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NBP2-16521-img0021.jpg "Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: FOXO3 Antibody [NBP2-16521] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:1000. Blue: Hoechst 33342 staining.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-16521-img0023.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse duodenum. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0028.jpg)
![<b>Genetic Strategies Validation. </b>Chromatin Immunoprecipitation (ChIP): FOXO3 Antibody [NBP2-16521] - (D) ChIP assay for LMOD1 and EGFR (as a positive control region) in HCASMC chromatin lysates immunoprecipitated with antibodies to FOXO3 or a negative control rabbit IgG. n = 3. (E) Allele specific ChIP (haploChIP) for FOXO3 protein in DNA derived from cultured HCASMC ChIP experiments. DNA from cell line homozygous for the ancestral allele was used as a positive control and arbitrarily set to 1. Values represent mean +/- standard deviation of triplicates. Similar results were observed from n = 4 independent lines for each genotype. (F) Quantitative RT-PCR analysis of LMOD1 in HCASMCs following knock down of endogenous FOXO3 (F) or overexpression of FOXO3 (G). The results were reproduced in n = 3 independent experiments. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1007755) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Chromatin-Immunoprecipitation-ChIP-NBP2-16521-img0030.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - 50 ug of mouse brain whole cell lysate). Antibody at 1:500.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Western-Blot-NBP2-16521-img0002.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FOXO3 Antibody [NBP2-16521] - Non-transfected (-) and transfected (+) C2C12 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NBP2-16521-img0015.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Huh-7 xenograft, using FOXO3A antibody at 1:500 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0003.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat colon. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0024.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse testis. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-Negative-NBP2-16521-img0025.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0026.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-Negative-NBP2-16521-img0027.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Jurkat whole cell lysate/extract A. Control with 2 ug of preimmune rabbit IgG B. Immunoprecipitation of FOXO3A protein by 2 ug of FOXO3A antibody 5% SDS-PAGE The immunoprecipitated FOXO3A protein was detected by FOXO3A antibody diluted at 1:1000. EasyBlot anti-rabbit IgG was used as a secondary reagent.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NBP2-16521-img0029.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - LMOD1 expression is mediated by PDGF-BB-FOXO3 signaling cascade.(A) UCSC Browser screenshot of the LMOD1 CAD locus at chromosome 1q32.1 highlighting the candidate causal variant, rs34091558, overlapping ATAC-seq open chromatin & RNA-seq tracks in HCASMCs treated with PDGF-BB (n = 2 biological replicates). Genomic coordinates refer to hg19 assembly. Quantitative RT-PCR (B) & Western blotting (C) data revealing PDGF-BB & phosphorylated-FOXO3 (P-FOXO3) mediated LMOD1 expression. (D) Co-expression microarray analysis performed in a cohort of carotid atherosclerotic plaques (n = 127) indicating that LMOD1 & FOXO3 are positively correlated in arterial tissues. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30444878), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202415345315.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Chemotherapy-induced A2BR expression promotes FOXO3 binding on pluripotency factor genes through decreased H3K27me3 & increased H3K27ac chromatin marks. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h & chromatin immunoprecipitation (ChIP) was performed with antibody against FOXO3. Primers flanking the FOXO3 binding site in the NANOG, SOX2 & KLF4 gene (A) were used for qPCR (B; mean ± SEM; n = 3); **p < 0.01, ***p < 0.001 vs. NTC/EV-V; #p < 0.05, ##p < 0.01 vs. NTC/EV-P; ^^p < 0.01, ^^^p < 0.0001 vs. A2BR shRNA/EV-P; ns, not significant. C & E, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & immunoblot assays were performed. D, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h. Cytosolic & nuclear lysates were prepared, & immunoblot assays were performed. F-H, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or 10 nM P for 72 h. ChIP was performed using antibodies against H3K27me3 (F), H3K27ac (G), or Histone H3 (H) followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-3102024161229.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - SMARCD3 knockdown blocks paclitaxel-induced FOXO3 binding on pluripotency factor genes & inhibits BCSC enrichment. A, MDA-MB-231 cells were transfected with vector encoding NTC or either of two shRNAs targeting SMARCD3 (#1 & #2), & immunoblot assay was performed. B-D, MDA-MB-231 NTC or SMARCD3 knockdown subclones were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h, & ALDH (B; mean ± SEM; n = 3), mammosphere (C; mean ± SEM; n = 4), & qPCR (D; mean ± SEM; n = 3) assays were performed; *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. E-I, MDA-MB-231 NTC or SMARCD3 knockdown subclones were treated with V or 10 nM P for 72 h. ChIP was performed using antibodies against FOXO3 (E), H3K27me3 (F), H3K27ac (G), KDM6A (H), or p300 (I), followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 4); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202416114757.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Chemotherapy-induced A2BR expression promotes FOXO3 binding on pluripotency factor genes through decreased H3K27me3 & increased H3K27ac chromatin marks. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h & chromatin immunoprecipitation (ChIP) was performed with antibody against FOXO3. Primers flanking the FOXO3 binding site in the NANOG, SOX2 & KLF4 gene (A) were used for qPCR (B; mean ± SEM; n = 3); **p < 0.01, ***p < 0.001 vs. NTC/EV-V; #p < 0.05, ##p < 0.01 vs. NTC/EV-P; ^^p < 0.01, ^^^p < 0.0001 vs. A2BR shRNA/EV-P; ns, not significant. C & E, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & immunoblot assays were performed. D, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h. Cytosolic & nuclear lysates were prepared, & immunoblot assays were performed. F-H, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or 10 nM P for 72 h. ChIP was performed using antibodies against H3K27me3 (F), H3K27ac (G), or Histone H3 (H) followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202416121916.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - A2BR decreases H3K27me3 & increases H3K27ac marks through recruitment of KDM6A & p300 at FOXO3 binding sites of pluripotency factor genes. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h. ChIP was performed using antibodies against KDM6A (A) or p300 (B) followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; ##p < 0.01, ###p < 0.001 vs. NTC-P; ^^p < 0.01, ^^^p < 0.0001 vs. A2BR shRNA/EV-P; ns, not significant. C, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & immunoblot assays were performed. D, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & nuclear lysates were prepared. Immunoprecipitation (IP) was performed using FOXO3 antibody or control IgG followed by immunoblot assays. NL, nuclear protein lysate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-31020241612240.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: FOXO3 Antibody [NBP2-16521] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-1610202419405793.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0014.jpg "Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FOXO3 Antibody [NB100-614] - Analysis of FOXO3 in human B cell lymphoma using anti-FOXO3 antibody .Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-614-img0007.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NB100-614] - Sample: FFPE section of human ovarian carcinoma (left) and mouse renal cell carcinoma (right). Antibody: Affinity purified rabbit anti-FOXO3a used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-NB100-614-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Detection of Human and Mouse FOXO3a by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0011.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - FOXO3 Protein expression levels both control group and exercise group for skeletal muscles. Image submitted by a verified customer review *{Mouse WB}*](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0012.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: FOXO3 Antibody [NB100-614] - Detection of human FOXO3a by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from MCF-7 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for IP at 6 ug/mg lysate. FOXO3a was also immunoprecipitated by rabbit anti-FOXO3a antibody NB100-613. For blotting immunoprecipitated FOXO3a, NB100-614 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NB100-614-img0013.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Representative Western blotting results. Foxo1- or Foxo1/3-specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM-cerebellum, STR-striatum, SCD-spinal cord, CTX-cortex, BST-brain stem, MDB-midbrain, HPC-hippocampus.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Knockout-Validated-NB100-614-img0015.jpg)
![Western Blot: Rabbit Polyclonal FOXO3 Antibody [NB100-614] - Analysis of FOXO3 and FOXM1in parental HCT-116 and HCT-116-FUR cells. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-614_rabbit-polyclonal-foxo3-antibody-western-blot-1652024104015.png)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415541916.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415535143.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155456.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155375.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415525289.jpg)
![Western Blot: FOXO3 Antibody [NB100-613] - Detection of Human and Mouse FOXO3a by Western Blot. Samples: Whole cell lysate (50 ug) from 293T, Jurkat, and mouse TCMK-1 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-613 used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-613-img0017.jpg "<b>Biological Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-613] - Detection of Human and Mouse FOXO3a by Western Blot. Samples: Whole cell lysate (50 ug) from 293T, Jurkat, and mouse TCMK-1 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-613 used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: FOXO3 Antibody [NB100-613] - Sample: FFPE sections of human ovarian carcinoma (left) and mouse renal cell carcinoma (right). Antibody: Affinity purified rabbit anti-fs18 FOXO3a fs20 used at a dilution of 1:500 (2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-NB100-613-img0015.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: FOXO3 Antibody [NB100-613] - Detection of Human FOXO3a on HeLa whole cell lysate using NB100-613. FOXO3a was also immunoprecipitated using NB100-614.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-613-img0014.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: FOXO3 Antibody [NB100-613] - Detection of human FOXO3a by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from MCF-7 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-613 used for IP at 6 ug/mg lysate. FOXO3a was also immunoprecipitated by rabbit anti-FOXO3a antibody NB100-614. For blotting immunoprecipitated FOXO3a, NB100-613 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NB100-613-img0018.jpg)
![Western Blot: FOXO3 [p Ser253] Antibody [NB100-81929] - Analysis of extracts from NIH/3T3 cells using FKHRL1 (Ab-253) antibody (Lane 1 and 2) and FKHRL1 (phospho-Ser253) antibody (Lane 3 and 4).](http://images.novusbio.com/fullsize/FOXO3-[p-Ser253]-Antibody-Western-Blot-NB100-81929-img0007.jpg "Western Blot: FOXO3 [p Ser253] Antibody [NB100-81929] - Analysis of extracts from NIH/3T3 cells using FKHRL1 (Ab-253) antibody (Lane 1 and 2) and FKHRL1 (phospho-Ser253) antibody (Lane 3 and 4).")
![Immunohistochemistry-Paraffin: FOXO3 [p Ser253] Antibody [NB100-81929] - Analysis of paraffin-embedded human breast carcinoma tissue using FKHRL1 (phospho-Ser253) antibody.](http://images.novusbio.com/fullsize/FOXO3-[p-Ser253]-Antibody-Immunohistochemistry-Paraffin-NB100-81929-img0006.jpg)
![Western Blot: FOXO3 [p Ser253] Antibody [NB100-81929] - Western Blot analysis of HeLa cells using NB100-81929 diluted at 1:2000](http://images.novusbio.com/fullsize/nb100-81929_rabbit-polyclonal-foxo3-p-ser253-antibody-23420241545354.jpg)
![Immunocytochemistry/Immunofluorescence: FOXO3 [p Ser253] Antibody [NB100-81929] - Staining of methanol-fixed HeLa cells using NB100-81929 (red).](http://images.novusbio.com/fullsize/nb100-81929_rabbit-polyclonal-foxo3-p-ser253-antibody-113202515145448.jpg)
![Western Blot: FOXO3 [p Ser425] Antibody [NBP3-16945] - Western blot analysis of extracts of K-562 cells, using FOXO3 antibody (NBP3-16945) at 1:1000 dilution.K-562 cells were treated by 10% FBS at 37C for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s.](http://images.novusbio.com/fullsize/FOXO3-[p-Ser425]-Antibody-Western-Blot-NBP3-16945-img0004.jpg "Western Blot: FOXO3 [p Ser425] Antibody [NBP3-16945] - Western blot analysis of extracts of K-562 cells, using FOXO3 antibody (NBP3-16945) at 1:1000 dilution.K-562 cells were treated by 10% FBS at 37C for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s.")
![Immunohistochemistry-Paraffin: FOXO3 [p Ser425] Antibody [NBP3-16945] - Immunohistochemistry of paraffin-embedded mouse heart using FOXO3 Rabbit pAb (NBP3-16945) at dilution of 1:250 (40x lens).Perform high pressure antigen retrieval with 10 mM citrate buffer pH 6.0 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/FOXO3-[p-Ser425]-Antibody-Immunohistochemistry-Paraffin-NBP3-16945-img0003.jpg)
![Immunohistochemistry-Paraffin: FOXO3 [p Ser425] Antibody [NBP3-16945] - Immunohistochemistry of paraffin-embedded rat kidney using FOXO3 Rabbit pAb (NBP3-16945) at dilution of 1:250 (40x lens).Perform high pressure antigen retrieval with 10 mM citrate buffer pH 6.0 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/FOXO3-[p-Ser425]-Antibody-Immunohistochemistry-Paraffin-NBP3-16945-img0001.jpg)
![Immunohistochemistry-Paraffin: FOXO3 [p Ser425] Antibody [NBP3-16945] - Immunohistochemistry of paraffin-embedded human lung cancer using FOXO3 Rabbit pAb (NBP3-16945) at dilution of 1:250 (40x lens).Perform high pressure antigen retrieval with 10 mM citrate buffer pH 6.0 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/FOXO3-[p-Ser425]-Antibody-Immunohistochemistry-Paraffin-NBP3-16945-img0002.jpg)
![Immunohistochemistry: FOXO3 Antibody (1E2) [NBP3-26571] - Image of FOXO3 Antibody (1E2) diluted at 1:180 and staining in paraffin-embedded human endometrial cancer performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.](http://images.novusbio.com/fullsize/nbp3-26571_rabbit-foxo3-mab-1e2-2722024850466.jpg "Immunohistochemistry: FOXO3 Antibody (1E2) [NBP3-26571] - Image of FOXO3 Antibody (1E2) diluted at 1:180 and staining in paraffin-embedded human endometrial cancer performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.")
![Immunohistochemistry: FOXO3 Antibody (1E2) [NBP3-26571] - Image of FOXO3 Antibody (1E2) diluted at 1:180 and staining in paraffin-embedded human endometrial cancer performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.](http://images.novusbio.com/fullsize/nbp3-26571_rabbit-foxo3-mab-1e2-2722024847198.jpg)
![Western Blot: FOXO3 Antibody (1E2) [NBP3-26571] - Positive Western Blot detected in: 293 whole cell lysate, Jurkat whole cell lysate, SH-SY5Y whole cell lysate, U87 whole cell lysate. All lanes: FOXO3 Antibody at 1.8ug/ml. Secondary: Goat polyclonal to rabbit IgG at 1/50000 dilution. Predicted band size: 72, 49 KDa Observed band size: 72-90 KDa](http://images.novusbio.com/fullsize/nbp3-26571_rabbit-foxo3-mab-1e2-28220241136307.jpg)
![Immunocytochemistry/Immunofluorescence: FOXO3 Antibody (1E2) [NBP3-26571] - Staining of PC3 cells with FOXO3 Antibody (1E2) at 1:60, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-conjugated Goat Anti-Rabbit IgG (H+L).](http://images.novusbio.com/fullsize/nbp3-26571_rabbit-foxo3-mab-1e2-28220241312244.jpg)
![Immunohistochemistry: FOXO3 [p Ser253] Antibody (1E1) [NBP3-26424] - Image of FOXO3 [p Ser253] Antibody (1E1) diluted at 1:100 and staining in paraffin-embedded human breast cancer performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.](http://images.novusbio.com/fullsize/nbp3-26424_rabbit-foxo3-p-ser-253-mab-1e1-262202415355710.jpg "Immunohistochemistry: FOXO3 [p Ser253] Antibody (1E1) [NBP3-26424] - Image of FOXO3 [p Ser253] Antibody (1E1) diluted at 1:100 and staining in paraffin-embedded human breast cancer performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.")
![Immunohistochemistry: FOXO3 [p Ser253] Antibody (1E1) [NBP3-26424] - Image of FOXO3 [p Ser253] Antibody (1E1) diluted at 1:100 and staining in paraffin-embedded human breast cancer performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.](http://images.novusbio.com/fullsize/nbp3-26424_rabbit-foxo3-p-ser-253-mab-1e1-2722024857334.jpg)
![Western Blot: FOXO3 [p Ser253] Antibody (1E1) [NBP3-26424] - Positive Western Blot detected in Hela whole cell lysate, 293 whole cell lysate, A549 whole cell lysate. All lanes: FOXO3 [p Ser253] Antibody at 0.96ug/ml. Secondary: Goat polyclonal to rabbit IgG at 1/50000 dilution. Predicted band size: 97 KDa Observed band size: 97 KDa](http://images.novusbio.com/fullsize/nbp3-26424_rabbit-foxo3-p-ser-253-mab-1e1-282202411442618.jpg)
![Immunohistochemistry: FOXO3 [p Ser 253] Antibody (SR2309) [NBP3-21531] - Immunohistochemical analysis of paraffin-embedded human uterus cancer, using NBP3-21531.](http://images.novusbio.com/fullsize/nbp3-21531_rabbit-foxo3-p-ser-253-mab-sr2309-5720231523498.jpg "Immunohistochemistry: FOXO3 [p Ser 253] Antibody (SR2309) [NBP3-21531] - Immunohistochemical analysis of paraffin-embedded human uterus cancer, using NBP3-21531.")
![Western Blot: FOXO3 [p Ser 253] Antibody (SR2309) [NBP3-21531] - Western blot analysis using NBP3-21531 in MCF-7 cell lysate treated with IGF.](http://images.novusbio.com/fullsize/nbp3-21531_rabbit-foxo3-p-ser-253-mab-sr2309-57202316112178.jpg)